Akebia Therapeutics has reported its first-quarter results, prompting analysts to update their estimates. The company's stock has risen due to optimism about its clinical pipeline, particularly its anemia drug. Additionally, Akebia has been involved in various activities, including lobbying and awarding stock options to new employees, although the impact of these actions on the company is unclear.